- Home
- MTZ vs PCVX Comparison
MTZ vs PCVX Comparison
Compare MTZ & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTZ | PCVX |
|---|---|---|
| Founded | 1929 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 6.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MTZ | PCVX |
|---|---|---|
| Price | $242.29 | $46.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 7 |
| Target Price | ★ $231.37 | $105.00 |
| AVG Volume (30 Days) | 858.6K | ★ 1.1M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 270.77 | N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $13,762,473,000.00 | N/A |
| Revenue This Year | $15.49 | N/A |
| Revenue Next Year | $10.15 | N/A |
| P/E Ratio | $57.72 | ★ N/A |
| Revenue Growth | ★ 12.99 | N/A |
| 52 Week Low | $99.70 | $27.66 |
| 52 Week High | $249.21 | $93.77 |
Technical Indicators
Market Signals| Indicator | MTZ | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 65.68 | 52.91 |
| Support Level | $219.26 | $44.57 |
| Resistance Level | $229.59 | $49.55 |
| Average True Range (ATR) | 8.87 | 2.13 |
| MACD | 0.75 | 0.15 |
| Stochastic Oscillator | 80.38 | 52.90 |
Price Performance
Historical ComparisonAbout MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.